Ionis Antisense Oligonuleotide Drug IONIS-HTTRX is Safe and Decreases Levels of Toxic Huntington’s Disease Protein in Cerebrospinal Fluid.
In a statement released today, Ionis Pharmaceuticals announced study results demonstrating for the first time that their drug (IONIS-HTTRX) lowered levels of the abnormal protein causing Huntington’s disease in cerebrospinal fluid, and that this approach was safe and well tolerated in humans. Link: http://ir.ionispharma.com/news-releases/news-release-details/ionis-pharmaceuticals-licenses-ionis-htt-rx-partner-following The IONIS-HTTRx Study: The IONIS-HTTRX trial enrolled 46 patients with […]